Rosetta Receives Notice of Allowance for U.S. Patent for Ovarian Cancer Treatment
News Jul 12, 2014
Rosetta Genomics Ltd. has announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 13/977,797, entitled "Compositions and Methods for Treatment of Ovarian Cancer." The patent relates to inhibition of miR-210 for the treatment of ovarian cancer.
Treatment for advanced ovarian carcinoma is typically based on the combination of surgery and chemotherapy. The objective of surgical intervention in patients suffering from advanced disease is to perform cyto-reduction to minimal residual disease in the abdominal cavity. Surgery is followed by adjuvant platinum based chemotherapy. Although 80-90% of patients initially respond to first line treatment, most will either progress during therapy or recur after complete remission. Ovarian cancer causes more deaths than any other gynecologic cancer.
"This new patent allowance complements and extends the broad intellectual property protection we have established for oncology therapeutics and represents a valuable addition to our microRNA patent estate," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "Ovarian cancer remains a serious unmet medical need where there is a great demand for effective new therapies. microRNAs represent potential targets for the development of novel drugs and our growing patent portfolio for oncology therapeutics represents a valuable asset for development and/or monetization. Rosetta is a pioneer of microRNA technology and our broad and expanding patent portfolio will continue to protect and maintain our leadership position, as the vast potential of microRNA technologies is becoming realized."
"Rosetta has previously shown that microRNA-based diagnostics can provide significant insights into predicting response to platinum-based therapeutic regimens, which are the first line treatment for ovarian cancer. This capability is of greater value today as new agents are emerging with efficacy in ovarian cancer that provide potential alternatives when platinum is determined to be of unlikely benefit and may, therefore, be added to our clinical diagnostic portfolio going forward to leverage investments in our commercial and laboratory infrastructure," added Dr. E. Robert Wassman, Chief Medical Officer of Rosetta Genomics.
Rosetta's robust patent portfolio includes 36 issued patents, including 32 in the U.S. In addition, Rosetta has 49 patent applications pending, of which 27 are in the U.S.